Literature DB >> 24524785

Hypoxic culture conditions for Mesenchymal Stromal/Stem Cells from Wharton's jelly: a critical parameter to consider in a therapeutic context.

Loic Reppel, Talar Margossian, Layale Yaghi, Philippe Moreau, Nathalie Mercier, Leonore Leger, Sebastien Hupont, Jean-Francois Stoltz, Daniele Bensoussan, Celine Huselstein1.   

Abstract

Mesenchymal Stromal/Stem Cells from human Wharton's jelly (WJ-MSC) are an abundant and interesting source of stem cells for applications in cell and tissue engineering. Their fetal origin confers specific characteristics compared to Mesenchymal Stromal/Stem Cells isolated from human bone marrow (BM-MSC). The aim of this work was to optimize WJ-MSC culture conditions for their subsequent clinical use. We focused on the influence of oxygen concentration during monolayer expansion on several parameters to characterize MSC. Our work distinguished WJ-MSC from BM-MSC in terms of proliferation, telomerase activity and adipogenic differentiation. We also showed that hypoxia had a beneficial effect on proliferation potential, clonogenic capacity and to a lesser extent, on HLA-G expression of WJ-MSC during their expansion. Moreover, we reported for the first time an increase in chondrogenic differentiation when WJ-MSC were expanded under hypoxia. In an allogeneic therapeutic context, production of clinical batches requires generating high numbers of MSC whilst maintaining the cells' properties. Considering our results, hypoxia will be an important parameter to take into account. In addition, the clinical use of WJ-MSC would provide significant numbers of cells with maintenance of their proliferation and differentiation potential, particularly their chondrogenic potential. Due to their chondrogenic differentiation potential, WJ-MSC promise to be an interesting source of MSC for cell therapy or tissue engineering for cartilage repair and/or regeneration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24524785     DOI: 10.2174/1574888x09666140213204850

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  12 in total

1.  Chondrogenic induction of mesenchymal stromal/stem cells from Wharton's jelly embedded in alginate hydrogel and without added growth factor: an alternative stem cell source for cartilage tissue engineering.

Authors:  Loïc Reppel; Jessica Schiavi; Naceur Charif; Léonore Leger; Hao Yu; Astrid Pinzano; Christel Henrionnet; Jean-François Stoltz; Danièle Bensoussan; Céline Huselstein
Journal:  Stem Cell Res Ther       Date:  2015-12-30       Impact factor: 6.832

2.  Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells as a Potential Source for Cartilage and Bone Regeneration: An In Vitro Study.

Authors:  A Marmotti; S Mattia; F Castoldi; A Barbero; L Mangiavini; D E Bonasia; M Bruzzone; F Dettoni; R Scurati; G M Peretti
Journal:  Stem Cells Int       Date:  2017-11-16       Impact factor: 5.443

3.  In vitro chondrogenesis of Wharton's jelly mesenchymal stem cells in hyaluronic acid-based hydrogels.

Authors:  Ewelina Aleksander-Konert; Piotr Paduszyński; Alicja Zajdel; Zofia Dzierżewicz; Adam Wilczok
Journal:  Cell Mol Biol Lett       Date:  2016-08-12       Impact factor: 5.787

4.  The Hypoxia-Mimetic Agent Cobalt Chloride Differently Affects Human Mesenchymal Stem Cells in Their Chondrogenic Potential.

Authors:  Gabriella Teti; Stefano Focaroli; Viviana Salvatore; Eleonora Mazzotti; Laura Ingra'; Antonio Mazzotti; Mirella Falconi
Journal:  Stem Cells Int       Date:  2018-03-13       Impact factor: 5.443

5.  Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton's Jelly, an Extraembryonic Source.

Authors:  Caroline Laroye; Mélanie Gauthier; Hélène Antonot; Véronique Decot; Loïc Reppel; Danièle Bensoussan
Journal:  J Clin Med       Date:  2019-12-14       Impact factor: 4.241

Review 6.  Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.

Authors:  J-F Stoltz; N de Isla; Y P Li; D Bensoussan; L Zhang; C Huselstein; Y Chen; V Decot; J Magdalou; N Li; L Reppel; Y He
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

7.  Phenotypic, Functional, and Safety Control at Preimplantation Phase of MSC-Based Therapy.

Authors:  Wioletta Lech; Anna Figiel-Dabrowska; Anna Sarnowska; Katarzyna Drela; Patrycja Obtulowicz; Bartlomiej Henryk Noszczyk; Leonora Buzanska; Krystyna Domanska-Janik
Journal:  Stem Cells Int       Date:  2016-08-29       Impact factor: 5.443

8.  Umbilical cord-derived mesenchymal stromal cells: predictive obstetric factors for cell proliferation and chondrogenic differentiation.

Authors:  Léonore Avercenc-Léger; Philippe Guerci; Jean-Marc Virion; Ghislaine Cauchois; Sébastien Hupont; Rachid Rahouadj; Jacques Magdalou; Jean-François Stoltz; Danièle Bensoussan; Céline Huselstein; Loïc Reppel
Journal:  Stem Cell Res Ther       Date:  2017-07-05       Impact factor: 6.832

9.  Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2.

Authors:  Layale Yaghi; Isabelle Poras; Renata T Simoes; Eduardo A Donadi; Jörg Tost; Antoine Daunay; Bibiana Sgorla de Almeida; Edgardo D Carosella; Philippe Moreau
Journal:  Oncotarget       Date:  2016-09-27

10.  Assessment of the Neuroprotective and Stemness Properties of Human Wharton's Jelly-Derived Mesenchymal Stem Cells under Variable (5% vs. 21%) Aerobic Conditions.

Authors:  Ewelina Tomecka; Wioletta Lech; Marzena Zychowicz; Anna Sarnowska; Magdalena Murzyn; Tomasz Oldak; Krystyna Domanska-Janik; Leonora Buzanska; Natalia Rozwadowska
Journal:  Cells       Date:  2021-03-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.